Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Q32 Bio ( (QTTB) ) has shared an update.

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming apart due to an error in patient ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the ...

Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.

Short interest in Q32 Bio Inc (NASDAQ:QTTB) increased during the last reporting period, rising from 678.64K to 686.07K. This put -% of the company's publicly available shares short. Short interest ...